Create Account
B
Novo Nordisk A/S NVO
$159.14 $1.050.66%
Recommendation
Buy
Prev Close
$158.09
Volume
1,142,969
Avg Vol (90D)
1,387,861
Market Cap
$353.18B
Dividend & Yield
$1.25(0.79%)
52-Week Range
$95.02 - $158.11
P/E (TTM)
45.66
EPS (TTM)
$3.46
My Lists My Alerts
Report
Rating
Reward
A+
Excellent
Risk
C
Fair
Rating Factors
Growth Index
Excellent
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Excellent
Volatility Index
Good
Dividend Index
Good
Headlines
'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drug
4/1/2023 - NPR Topics: Business
Weight Loss Drug Saxenda May Make WHO List: Could Help Make It Cheaper Worldwide
3/31/2023 - Forbes.com: Healthcare News
bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4
3/31/2023 - Zacks Investment Research
Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now
3/31/2023 - Zacks Investment Research
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
3/31/2023 - Zacks Investment Research
Novo Nordisk A/S (NYSE:NVO) Shares Purchased by HB Wealth Management LLC
3/31/2023 - Zolmax
HB Wealth Management LLC Raises Holdings in Novo Nordisk A/S (NYSE:NVO)
3/31/2023 - Ticker Report
HB Wealth Management LLC Raises Holdings in Novo Nordisk A/S (NYSE:NVO)
3/31/2023 - Zolmax
Boston Trust Walden Corp Cuts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)
3/31/2023 - Zolmax
Only Electric Autos in 10 Years' Time?
3/30/2023 - Zacks Investment Research
3 Stocks That Could Benefit From the Ozempic Craze
3/30/2023 - Fool.com Headlines
Novo Nordisk A/S (NYSE:NVO) Stock Position Lessened by Vestmark Advisory Solutions Inc.
3/30/2023 - Zolmax
Novo Nordisk A/S (NYSE:NVO) Stock Position Lessened by Vestmark Advisory Solutions Inc.
3/30/2023 - Ticker Report
Griffin Asset Management Inc. Purchases 190 Shares of Novo Nordisk A/S (NYSE:NVO)
3/30/2023 - Ticker Report
Stopping Novo Nordisk's Wegovy, Ozempic may lead to regaining weight - report
3/30/2023 - SeekingAlpha.com: All News
Novo Nordisk's Obesity Drug May Find Place On World Health Organization's 'Essential Medicines List'
3/29/2023 - Benzinga
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
3/29/2023 - Zacks Investment Research
Adobe (ADBE) Boosts Digital Experience With Latest Innovations
3/29/2023 - Zacks Investment Research
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
3/29/2023 - Fool.com Headlines
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
3/28/2023 - Zacks Investment Research
Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU
3/28/2023 - Zacks Investment Research
Novo Nordisk (NVO) is a Great Momentum Stock: Should You Buy?
3/28/2023 - Zacks Investment Research
CFM Wealth Partners LLC Purchases New Shares in Novo Nordisk A/S (NYSE:NVO)
3/28/2023 - Ticker Report
Tsfg LLC Acquires New Holdings in Novo Nordisk A/S (NYSE:NVO)
3/28/2023 - Ticker Report
Strategic Investment Advisors MI Takes Position in Novo Nordisk A/S (NYSE:NVO)
3/28/2023 - Ticker Report
Income Statement
Total Revenue (TTM)
$25.03B
EBITDA (TTM)
$11.66B
EBIT (TTM)
$10.71B
Net Income (TTM)
$7.87B
Balance Sheet
Total Assets (Q)
$34.66B
Total Debt (Q)
$3.70B
Total Liabilities (Q)
$22.67B
Book Value Per Share (Q)
$5.33
Cash Flow
Cash from Operations (TTM)
$11.25B
Cash from Investing (TTM)
-$3.46B
Cash from Financing (TTM)
-$7.41B
Net Change in Cash (TTM)
$344.83M
Filings
Filing Date
Wednesday, February 1, 2023
Period Date
Saturday, December 31, 2022
Next Filing
Week of Apr 24 and 28 (est)
Price History
Loading...
Beta
0.60
7-Day Total Return
9.11%
30-Day Total Return
15.40%
60-Day Total Return
17.02%
90-Day Total Return
41.09%
Year to Date Total Return
16.86%
1-Year Total Return
44.66%
2-Year Total Return
140.79%
3-Year Total Return
173.85%
5-Year Total Return
252.27%
52-week Low
Sep 26, 2022 - $95.02
52-week High
Mar 30, 2023 - $158.11
Valuation
Market Cap
$353.18B - Mega Cap
Enterprise Value
$353.50B
Price/Sales (TTM)
14.29
Price/Book (Q)
29.66
Dividends and Shares
Shares Outstanding
2.26B
Dividend Per Share (Most Recent)
$0.8468
Dividend Per Share (TTM)
$1.25
Corporate Info
Website
www.novonordisk.com
Phone Number
45 44 44 88 88
Address
Novo AllE 1
Bagsvaerd, 2880
Country
Denmark
Year Founded
1923
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity... more
NYSE 03/31/2023 4:00PM Eastern Quotes delayed
Weiss Ratings